1. Wertheim HFL, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, et al.
The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis.
United States; 2005;5:751–62.
2. Williams RE. Healthy carriage of Staphylococcus aureus: its prevalence and importance.
Bacteriol Rev. United States; 1963;27:56–71.
3. Wyllie DH, Crook DW, Peto TEA. Mortality after Staphylococcus aureus bacteraemia
in two hospitals in Oxfordshire, 1997-2003: cohort study. BMJ. England; 2006;333:281.
4. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors
of mortality in Staphylococcus aureus Bacteremia. Clin Microbiol Rev. United States;
2012;25:362–86.
5. McMullan BJ, Bowen A, Blyth CC, Van Hal S, Korman TM, Buttery J, et al. Epidemiology
and Mortality of Staphylococcus aureus Bacteremia in Australian and New Zealand Children.
JAMA Pediatr. United States; 2016;170:979–86.
6. Gillet Y, Issartel B, Vanhems P, Fournet J-C, Lina G, Bes M, et al. Association
between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin
and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet
(London, England). England; 2002;359:753–9.
7. Gillet Y, Vanhems P, Lina G, Bes M, Vandenesch F, Floret D, et al. Factors predicting
mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus
containing Panton-Valentine leukocidin. Clin Infect Dis. United States; 2007;45:315–21.
8. Tong SYC, Davis JS, Eichenberger E, Holland TL, Fowler VGJ. Staphylococcus aureus
infections: epidemiology, pathophysiology, clinical manifestations, and management.
Clin Microbiol Rev. United States; 2015;28:603–61.
9. von Eiff C, Becker K, Machka K, Stammer H, Peters G. Nasal carriage as a source
of Staphylococcus aureus bacteremia. Study Group. N Engl J Med. United States; 2001;344:11–6.
10. Bai AD, Showler A, Burry L, Steinberg M, Ricciuto DR, Fernandes T, et al. Impact
of Infectious Disease Consultation on Quality of Care, Mortality, and Length of Stay
in Staphylococcus aureus Bacteremia: Results From a Large Multicenter Cohort Study.
Clin Infect Dis. United States; 2015;60:1451–61.
11. Vogel M, Schmitz RPH, Hagel S, Pletz MW, Gagelmann N, Scherag A, et al. Infectious
disease consultation for Staphylococcus aureus bacteremia - A systematic review and
meta-analysis. J Infect. England; 2016;72:19–28.
12. Liu C, Bayer A, Cosgrove SE, Daum RS, Fridkin SK, Gorwitz RJ, et al. Clinical
practice guidelines by the infectious diseases society of america for the treatment
of methicillin-resistant Staphylococcus aureus infections in adults and children:
executive summary. Clin Infect Dis. United States; 2011;52:285–92.
13. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Torok ME, et
al. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis. United
States; 2011;11:208–22.
14. eTG complete [Internet]. Melbourne: Therapeutic Guidelines Limited; 2015 Mar.
15. Guidance on the Diagnosis and Management of PVL-Associated Staphylococcus aureus
Infections (PVL-SA) in England. In: Agency HP, editor. London, UK: HPA; 2008.
16. Gillet Y, Dumitrescu O, Tristan A, Dauwalder O, Javouhey E, Floret D, et al. Pragmatic
management of Panton-Valentine leukocidin-associated staphylococcal diseases. Int
J Antimicrob Agents. Netherlands; 2011;38:457–64.
17. Campbell AJ, Dotel R, Blyth CC, Davis JS, Tong SYC, Bowen AC. Adjunctive protein
synthesis inhibitor antibiotics for toxin suppression in Staphylococcus aureus infections:
a systematic appraisal. J Antimicrob Chemother. England; 2019;74:1-5
18. Lowy FD. Staphylococcus aureus infections. N Engl J Med. United States; 1998;339:520–32.
19. Dinges MM, Orwin PM, Schlievert PM. Exotoxins of Staphylococcus aureus. Clin Microbiol
Rev. United States; 2000;13:16–34, table of contents.
20. Foster TJ. Immune evasion by staphylococci. Nat Rev Microbiol. England; 2005;3:948–58.
21. Becker K, Friedrich AW, Lubritz G, Weilert M, Peters G, Von Eiff C. Prevalence
of genes encoding pyrogenic toxin superantigens and exfoliative toxins among strains
of Staphylococcus aureus isolated from blood and nasal specimens. J Clin Microbiol.
United States; 2003;41:1434–9.
22. Spaulding AR, Salgado-Pabon W, Kohler PL, Horswill AR, Leung DYM, Schlievert PM.
Staphylococcal and streptococcal superantigen exotoxins. Clin Microbiol Rev. United
States; 2013;26:422–47.
23. Peacock SJ, Moore CE, Justice A, Kantzanou M, Story L, Mackie K, et al. Virulent
combinations of adhesin and toxin genes in natural populations of Staphylococcus aureus.
Infect Immun. United States; 2002;70:4987–96.
24. Hewagama S, Spelman T, Woolley M, McLeod J, Gordon D, Einsiedel L. The Epidemiology
of Staphylococcus aureus and Panton-Valentine Leucocidin (pvl) in Central Australia,
2006-2010. BMC Infect Dis. England; 2016;16:382.
25. Ellington MJ, Hope R, Ganner M, Ganner M, East C, Brick G, et al. Is Panton-Valentine
leucocidin associated with the pathogenesis of Staphylococcus aureus bacteraemia in
the UK? J Antimicrob Chemother. England; 2007;60:402–5.
26. Shallcross LJ, Fragaszy E, Johnson AM, Hayward AC. The role of the Panton-Valentine
leucocidin toxin in staphylococcal disease: a systematic review and meta-analysis.
Lancet Infect Dis. United States; 2013;13:43–54.
27. Chua KYL, Monk IR, Lin Y-H, Seemann T, Tuck KL, Porter JL, et al. Hyperexpression
of alpha-hemolysin explains enhanced virulence of sequence type 93 community-associated
methicillin-resistant Staphylococcus aureus. BMC Microbiol. England; 2014;14:31.
28. Tong SYC, Lilliebridge RA, Holt DC, McDonald MI, Currie BJ, Giffard PM. High-resolution
melting analysis of the spa locus reveals significant diversity within sequence type
93 methicillin-resistant Staphylococcus aureus from northern Australia. Clin Microbiol
Infect. England; 2009;15:1126–31.
29. Kong C, Neoh H, Nathan S. Targeting Staphylococcus aureus Toxins: A Potential
form of Anti-Virulence Therapy. Toxins (Basel). Switzerland; 2016;8.
30. Verkaik NJ, Dauwalder O, Antri K, Boubekri I, de Vogel CP, Badiou C, et al. Immunogenicity
of toxins during Staphylococcus aureus infection. Clin Infect Dis. United States;
2010;50:61–8.
31. Poehlsgaard J, Douthwaite S. The bacterial ribosome as a target for antibiotics.
Nat Rev Microbiol. England; 2005;3:870–81.
32. Wilson DN. The A-Z of bacterial translation inhibitors. Crit Rev Biochem Mol Biol.
England; 2009;44:393–433.
33. Diep BA, Equils O, Huang DB, Gladue R. Linezolid effects on bacterial toxin production
and host immune response: review of the evidence. Curr Ther Res Clin Exp. United
States; 2012;73:86–102.
34. EAGLE H. Experimental approach to the problem of treatment failure with penicillin.
I. Group A streptococcal infection in mice. Am J Med. United States; 1952;13:389–99.
35. Stevens DL, Gibbons AE, Bergstrom R, Winn V. The Eagle effect revisited: efficacy
of clindamycin, erythromycin, and penicillin in the treatment of streptococcal myositis.
J Infect Dis. United States; 1988;158:23–8.
36. Stevens DL, Ma Y, Salmi DB, McIndoo E, Wallace RJ, Bryant AE. Impact of antibiotics
on expression of virulence-associated exotoxin genes in methicillin-sensitive and
methicillin-resistant Staphylococcus aureus. J Infect Dis. United States; 2007;195:202–11.
37. Kernodle DS, McGraw PA, Barg NL, Menzies BE, Voladri RK, Harshman S. Growth of
Staphylococcus aureus with nafcillin in vitro induces alpha-toxin production and increases
the lethal activity of sterile broth filtrates in a murine model. J Infect Dis. United
States; 1995;172:410–9.
38. Ohlsen K, Ziebuhr W, Koller KP, Hell W, Wichelhaus TA, Hacker J. Effects of subinhibitory
concentrations of antibiotics on alpha-toxin (hla) gene expression of methicillin-sensitive
and methicillin-resistant Staphylococcus aureus isolates. Antimicrob Agents Chemother.
United States; 1998;42:2817–23.
39. Dumitrescu O, Boisset S, Badiou C, Bes M, Benito Y, Reverdy M-E, et al. Effect
of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob
Agents Chemother. United States; 2007;51:1515–9.
40. Dumitrescu O, Badiou C, Bes M, Reverdy M-E, Vandenesch F, Etienne J, et al. Effect
of antibiotics, alone and in combination, on Panton-Valentine leukocidin production
by a Staphylococcus aureus reference strain. Clin Microbiol Infect. England; 2008;14:384–8.
41. Otto MP, Martin E, Badiou C, Lebrun S, Bes M, Vandenesch F, et al. Effects of
subinhibitory concentrations of antibiotics on virulence factor expression by community-acquired
methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. England; 2013;68:1524–32.
42. Arrieta AC, Bradley JS, Popejoy MW, Bensaci M, Grandhi A, Bokesch P, et al. Randomized
Multicenter Study Comparing Safety and Efficacy of Daptomycin Versus Standard-of-care
in Pediatric Patients With Staphylococcal Bacteremia. Pediatr Infect Dis J. United
States; 2018;37:893–900.
44. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions
for sepsis and organ failure and guidelines for the use of innovative therapies in
sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society
of Critical Care Medicine. Chest. United States; 1992;101:1644–55.
46. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference:
definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med.
United States; 2005;6:2–8.
47. McDanel JS, Roghmann M-C, Perencevich EN, Ohl ME, Goto M, Livorsi DJ, et al. Comparative
Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible
Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
Clin Infect Dis. United States; 2017;65:100–6.
48. Australian Medicines Handbook 2017 (online). Adelaide: Australian Medicines Handbook
Pty Ltd; 2017 Jan. Available from: https://amhonline.amh.net.au.
49. U.S. Department of Health and Human Services, National Institutes of Health, National
Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS)
Table for Grading the Severity of Adult and Pediatric Adverse Events, Corrected .
50. Tong SYC, Nelson J, Paterson DL, Fowler VGJ, Howden BP, Cheng AC, et al. CAMERA2
- combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection:
study protocol for a randomised controlled trial. Trials. England; 2016;17:170.
51. Coombs GW, Nimmo GR, Daly DA, Le TT, Pearson JC, Tan H-L, et al. Australian Staphylococcus
aureus Sepsis Outcome Programme annual report, 2013. Commun Dis Intell Q Rep. Australia;
2014;38:E309-19.
52. Coombs GW, Daley DA, Thin Lee Y, Pearson JC, Robinson JO, Nimmo GR, et al. Australian
Group on Antimicrobial Resistance Australian Staphylococcus aureus Sepsis Outcome
Programme annual report, 2014. Commun Dis Intell Q Rep. Australia; 2016;40:E244-54.
53. The Australian Group on Antimicrobial Resistance (AGAR) 2015 Australian Staphylococcus
aureus Sepsis Outcome Program (ASSOP). Staphpath 2017; 2017 25-26 February; Adelaide,
Australia; 2017.
54. Lewis JS 2nd, Jorgensen JH. Inducible clindamycin resistance in Staphylococci:
should clinicians and microbiologists be concerned? Clin Infect Dis. United States;
2005;40:280–5.
55. Hodille E, Badiou C, Bouveyron C, Bes M, Tristan A, Vandenesch F, et al. Clindamycin
suppresses virulence expression in inducible clindamycin-resistant Staphylococcus
aureus strains. Ann Clin Microbiol Antimicrob. England; 2018;17:38.